CMBA
XENE icon

C.M. Bidwell & Associates’s Xenon Pharmaceuticals XENE Stock Holding History

C.M. Bidwell & Associates’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9
Closed -$353 – 527
2024
Q4 		$353 Hold
9
– – ﹤0.01% 473
2024
Q3 		$354 Hold
9
– – ﹤0.01% 489
2024
Q2 		$351 Hold
9
– – ﹤0.01% 463
2024
Q1 		$387 Buy
+9
New +$414 ﹤0.01% 460

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

C.M. Bidwell & Associates's XENE Position: Q1 2025 in Review

C.M. Bidwell & Associates sold out of Xenon Pharmaceuticals (XENE) in Q1 2025, closing a stake of 9 shares — an estimated $353 sold.

C.M. Bidwell & Associates first reported a position in XENE in Q1 2024 and held it in 4 quarters. The position peaked at $387 in Q1 2024. 206 funds tracked by Wall St. Rank hold XENE as of Q1 2025.

  • C.M. Bidwell & Associates reported no remaining Xenon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 9 Xenon Pharmaceuticals shares in Q1 2025, an estimated $353.
  • C.M. Bidwell & Associates first reported a position in Xenon Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • C.M. Bidwell & Associates's Xenon Pharmaceuticals position peaked at $387 in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2025, filed 15 May 2025.